BEI
REGN icon

Benjamin Edwards Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

Benjamin Edwards Inc’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63M Buy
2,613
+560
+27% +$381K 0.01% 636
2026
Q1 		$1.59M Sell
2,053
-2,251
-52% -$1.72M 0.02% 613
2025
Q4 		$3.32M Sell
4,304
-132
-3% -$89.6K 0.04% 388
2025
Q3 		$2.49M Buy
4,436
+559
+14% +$316K 0.03% 444
2025
Q2 		$2.04M Buy
3,877
+1,922
+98% +$1.07M 0.03% 455
2025
Q1 		$1.24M Buy
1,955
+307
+19% +$211K 0.02% 522
2024
Q4 		$1.17M Sell
1,648
-1,489
-47% -$1.25M 0.02% 559
2024
Q3 		$3.3M Buy
3,137
+3,112
+12,448% +$3.46M 0.05% 337
2024
Q2 		$26K Buy
25
+4
+19% +$3.88K 0.01% 568
2024
Q1 		$20K Buy
+21
New +$20K ﹤0.01% 575
2023
Q4 		– Sell
-5
Closed -$4K – 662
2023
Q3 		$4K Hold
5
– – ﹤0.01% 608
2023
Q2 		$4K Hold
5
– – ﹤0.01% 625
2023
Q1 		$4K Hold
5
– – ﹤0.01% 643
2022
Q4 		$4K Sell
5
-33
-87% -$24.3K ﹤0.01% 648
2022
Q3 		$26K Hold
38
– – 0.01% 487
2022
Q2 		$22K Hold
38
– – 0.01% 511
2022
Q1 		$27K Sell
38
-15
-28% -$9.49K 0.01% 524
2021
Q4 		$33K Buy
+53
New +$32.6K 0.01% 463
2021
Q2 		– Sell
-31
Closed -$15K – 438
2021
Q1 		$15K Buy
+31
New +$15.1K 0.01% 322

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Benjamin Edwards Inc's REGN Position: Q2 2026 in Review

Benjamin Edwards Inc increased its Regeneron Pharmaceuticals (REGN) stake by 27% in Q2 2026, buying an estimated $381K and bringing the position to 2,613 shares worth $1.63M. The position accounts for 0.01% of the portfolio, ranked #636.

Benjamin Edwards Inc first reported a position in REGN in Q1 2021 and has held it in 19 quarters since. The position peaked at $3.32M in Q4 2025. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Benjamin Edwards Inc held 2,613 shares of Regeneron Pharmaceuticals worth $1.63M as of Q2 2026.
  • Benjamin Edwards Inc bought 560 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $381K.
  • Regeneron Pharmaceuticals made up 0.01% of Benjamin Edwards Inc's portfolio in Q2 2026, its #636 holding.
  • Benjamin Edwards Inc first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 19 quarters since.
  • Benjamin Edwards Inc's Regeneron Pharmaceuticals position peaked at $3.32M in Q4 2025.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Benjamin Edwards Inc's 13F filing for Q2 2026, filed 24 Jul 2026.